Alpha Cancer Technologies
PrivateLast Round
Seed
May 12, 2023
Est. Valuation
$50M
Total Funding Raised
$7.55M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Alpha Cancer Technologies operates in Healthcare & Life Sciences and is based in Toronto, Ontario. Its latest recorded funding round was a Corporate Funding round in December 2015.
Alpha Cancer Technologies is a biotechnology company that develops clinical-stage biologic drugs designed to treat immuno-oncology and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alpha Cancer Technologies Comparables
Compare Alpha Cancer Technologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cybrexa Therapeutics | 78% | |
| Adcentrx Therapeutics | 74% | |
| Bicycle Therapeutics | 72% |
For institutional investors. Book with your work email.
Alpha Cancer Technologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 12, 2023 | ||||
| Corporate Funding | Dec 2, 2015 | ||||
| Grant | Jun 21, 2010 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Alpha Cancer Technologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Research Council of Canada | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 37% MoM, reaching 2.2K.
- May 12, 2026
Monthly visitors increased 247% MoM.
For institutional investors. Book with your work email.
Alpha Cancer Technologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Alpha Cancer Technologies's valuation, stock price, and market status.
Is Alpha Cancer Technologies a public or private company?
Alpha Cancer Technologies is a private company.
What is the current stock price of Alpha Cancer Technologies?
Alpha Cancer Technologies is a private company, so its shares have no public market price. Caplight tracks Alpha Cancer Technologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alpha Cancer Technologies worth (valuation)?
Alpha Cancer Technologies's valuation is estimated at $50.0M based on funding round data.
Can I buy Alpha Cancer Technologies stock?
Alpha Cancer Technologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alpha Cancer Technologies's last funding round?
Alpha Cancer Technologies's most recent funding round was Seed on May 12, 2023.
Who are the main investors in Alpha Cancer Technologies?
Key investors in Alpha Cancer Technologies include National Research Council of Canada.
Will Alpha Cancer Technologies IPO soon?
No public IPO plans have been announced for Alpha Cancer Technologies.
How can I track Alpha Cancer Technologies secondary market activity?
Caplight tracks bids, offers, and trades in Alpha Cancer Technologies's shares on secondary markets.